Tarsus Pharmaceuticals, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for TARS, updated each market day.
TARS AI Sentiment
AI sees no strong directional signal for Tarsus Pharmaceuticals, Inc. Common Stock stock over the next 10 market days.
Prediction date: Sept. 17, 2026
Exact scores are in the SharePreds app
The precise prediction score for this stock, with buy and sell targets and a stop loss, updated every market day.
About Tarsus Pharmaceuticals, Inc. Common Stock
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
Sector
Exchange
Market Cap
$3,697,947,102
Cap Tier
Employees
370
Headquarters
IRVINE, CA
Listed Since
Oct. 16, 2020
Website
TARS Sentiment Trend: Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
TARS Volatility
Tarsus Pharmaceuticals, Inc. Common Stock has shown moderate price volatility over the last 5 trading days. Moderate volatility indicates normal market activity with typical price fluctuations.
